checkAd

    Ad hoc  853  0 Kommentare MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis - Seite 2

    HuCAL®, HuCAL GOLD®, HuCAL PLATINUM®, CysDisplay®, RapMAT®, arYla®, Ylanthia®, 100 billion high potentials®, Slonomics®, Lanthio Pharma® and LanthioPep® are registered trademarks of the MorphoSys Group.

    Humira® is a registered trademarks of AbbVie Inc.

    This communication contains certain forward-looking statements concerning the MorphoSys group of companies. The forward-looking statements contained herein represent the judgment of MorphoSys as of the date of this release and involve risks and uncertainties. Should actual conditions differ from the Company's assumptions, actual results and actions may differ from those anticipated. MorphoSys does not intend to update any of these forward-looking statements as far as the wording of the relevant press release is concerned.


    For more information, please contact:
    MorphoSys AG
    Dr. Claudia Gutjahr-Löser
    Head of Corporate Communications & IR

    Jochen Orlowski
    Associate Director Corporate Communications & IR

    Alexandra Goller
    Senior Manager Corporate Communications & IR

    Tel: +49 (0) 89 / 899 27-404
    investors@morphosys.com





    This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
    The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
    Source: MorphoSys AG via Globenewswire

    --- End of Message ---

    MorphoSys AG
    Lena-Christ-Str. 48 Martinsried / Munich Germany

    WKN: 663200;ISIN: DE0006632003;Index:TECH All Share,CDAX,Prime All Share,TecDAX,HDAX,MIDCAP;
    Listed: Freiverkehr in Börse Stuttgart,
    Freiverkehr in Hanseatische Wertpapierbörse zu Hamburg,
    Freiverkehr in Börse Berlin,
    Freiverkehr in Börse Düsseldorf,
    Freiverkehr in Bayerische Börse München,
    Freiverkehr in Niedersächsische Börse zu Hannover,
    Prime Standard in Frankfurter Wertpapierbörse,
    Regulierter Markt in Frankfurter Wertpapierbörse;


    Seite 2 von 2


    Diskutieren Sie über die enthaltenen Werte


    GlobeNewswire
    0 Follower
    Autor folgen

    Verfasst von GlobeNewswire
    Ad hoc MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis - Seite 2 MorphoSys AG / Keyword(s): Misc. matters / Ad hoc: MorphoSys Announces That Its Licensee Janssen Reports Positive Results From A Phase 3 Study of Guselkumab in Plaque Psoriasis . Ad hoc announcement according to § 15 WpHG. Processed and …

    Schreibe Deinen Kommentar

    Disclaimer